文献速递白血病造血干细胞移植与细胞治疗

泊那替尼联合氟达拉滨、阿糖胞苷、伊达比星和粒细胞集落刺激因子化疗治疗急变期慢性髓性白血病患者(MATCHPOINT):单臂、多中心、1/2期试验

Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial.
PubMed 文献 · Lancet Haematol · 2021-12-11

MATCHPOINT是一项在8个英国试验加速计划资助中心开展的单臂、多中心1/2期试验,纳入17例适合强化化疗的费城染色体阳性或BCR-ABL1阳性急变期慢性髓性白血病成人患者,接受泊那替尼联合FLAG-IDA方案治疗。EffTox模型确定泊那替尼最佳剂量为30 mg每日一次联合FLAG-IDA;16例可评估患者中11例(69%)在一周期后达第二次慢性期,4例(25%)发生剂量限制性毒性,12例(71%)桥接至异基因造血干细胞移植。

要点

  • 泊那替尼联合FLAG-IDA在急变期慢性髓性白血病中可诱导第二次慢性期,作为桥接异基因造血干细胞移植的挽救治疗。
  • EffTox模型确定泊那替尼最佳剂量为30 mg每日一次联合FLAG-IDA。
  • 治疗相关死亡3例(18%),作者认为不超出该极高危强化化疗人群的预期。

核心结论

  • 泊那替尼联合FLAG-IDA可在急变期慢性髓性白血病患者中诱导第二次慢性期,代表一种桥接异基因造血干细胞移植的活性挽救治疗。
  • 治疗相关死亡数不超出该极高危接受强化化疗人群的预期。
  • 高效的EffTox方法可作为超罕见癌症中新疗法研究的模型。

研究设计与样本

  • MATCHPOINT为无缝设计的1/2期、多中心试验,在8个英国试验加速计划资助的中心开展。
  • 纳入年龄≥16岁、费城染色体阳性或BCR-ABL1阳性、适合强化化疗的急变期慢性髓性白血病成人患者。
  • 患者接受最多2个周期泊那替尼联合FLAG-IDA;泊那替尼口服试验剂量为15 mg隔日一次至45 mg每日一次,起始剂量30 mg每日一次,从FLAG-IDA第1天至第28天给药。
  • 静脉氟达拉滨30 mg/m2用5天、阿糖胞苷2 g/m2用5天、伊达比星8 mg/m2用3天,皮下粒细胞集落刺激因子按当地方案使用。
  • 采用EffTox设计评估活性与耐受性;主要终点为满足预设活性阈值(诱导第二次慢性期,定义为血液学或次要细胞遗传学缓解)和耐受性阈值(剂量限制性毒性)的最佳泊那替尼剂量;分析按意向治疗进行。

主要发现

  • EffTox模型同时考虑临床缓解和剂量限制性毒性,确定泊那替尼最佳剂量为30 mg每日一次联合FLAG-IDA。
  • 16例可评估患者中11例(69%)在一个周期治疗后达第二次慢性期。
  • 4例(25%)患者发生剂量限制性毒性,包括心肌病和4级丙氨酸氨基转移酶升高、脑静脉窦血栓形成、3级淀粉酶升高及4级丙氨酸氨基转移酶升高。
  • 17例患者中12例(71%)接受异基因造血干细胞移植。
  • 最常见的3-4级非血液学不良事件为肺部感染(n=4 [24%])、发热(n=3 [18%])和低钙血症(n=3 [18%]);11例(65%)患者发生12起严重不良事件;3例(18%)患者死于治疗相关事件(心肌病、肺出血和骨髓再生障碍)。

关键数值与推荐

  • 泊那替尼最佳剂量为30 mg每日一次联合FLAG-IDA。
  • 第二次慢性期定义为血液学或次要细胞遗传学缓解。
  • 活性与耐受性阈值由EffTox模型预设,剂量限制性毒性包括心肌病和4级丙氨酸氨基转移酶升高、脑静脉窦血栓形成、3级淀粉酶升高及4级丙氨酸氨基转移酶升高。

临床怎么用

  • 作者认为泊那替尼联合FLAG-IDA可诱导第二次慢性期,作为桥接异基因造血干细胞移植的活性挽救治疗。
  • 作者认为治疗相关死亡数不超出该极高危接受强化化疗人群的预期。
  • 作者认为EffTox方法可作为超罕见癌症中新疗法研究的模型。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Outcomes for patients with blast-phase chronic myeloid leukaemia are poor. Long-term survival depends on reaching a second chronic phase, followed by allogeneic haematopoietic stem-cell transplantation (HSCT). We investigated whether the novel combination of the tyrosine-kinase inhibitor ponatinib with fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) could improve response and optimise allogeneic HSCT outcomes in patients with blast-phase chronic myeloid leukaemia. The aim was to identify a dose of ponatinib, which combined with FLAG-IDA, showed clinically meaningful activity and tolerability. METHODS: MATCHPOINT was a seamless, phase 1/2, multicentre trial done in eight UK Trials Acceleration Programme-funded centres. Eligible participants were adults (aged ≥16 years) with Philadelphia chromosome-positive or BCR-ABL1-positive blast-phase chronic myeloid leukaemia, suitable for intensive chemotherapy. Participants received up to two cycles of ponatinib with FLAG-IDA. Experimental doses of oral ponatinib (given from day 1 to day 28 of FLAG-IDA) were between 15 mg alternate days and 45 mg once daily and the starting dose was 30 mg once daily. Intravenous fludarabine (30 mg/m2 for 5 days), cytarabine (2 g/m2 for 5 days), and idarubicin (8 mg/m2 for 3 days), and subcutaneous granulocyte colony-stimulating factor (if used), were delivered according to local protocols. We used an innovative EffTox design to investigate the activity and tolerability of ponatinib-FLAG-IDA; the primary endpoints were the optimal ponatinib dose meeting prespecified thresholds of activity (inducement of second chronic phase defined as either haematological or minor cytogenetic response) and tolerability (dose-limiting toxicties). Analyses were planned on an intention-to-treat basis. MATCHPOINT was registered as an International Standard Randomised Controlled Trial, ISRCTN98986889, and has completed recruitment; the final results are presented. FINDINGS: Between March 19, 2015, and April 26, 2018, 17 patients (12 men, five women) were recruited, 16 of whom were evaluable for the coprimary outcomes. Median follow-up was 41 months (IQR 36-48). The EffTox model simultaneously considered clinical responses and dose-limiting toxicities, and determined the optimal ponatinib dose as 30 mg daily, combined with FLAG-IDA. 11 (69%) of 16 patients were in the second chronic phase after one cycle of treatment. Four (25%) patients had a dose-limiting toxicity (comprising cardiomyopathy and grade 4 increased alanine aminotransferase, cerebral venous sinus thrombosis, grade 3 increased amylase, and grade 4 increased alanine aminotransferase), fulfilling the criteria for clinically relevant activity and toxicity. 12 (71%) of 17 patients proceeded to allogeneic HSCT. The most common grade 3-4 non-haematological adverse events were lung infection (n=4 [24%]), fever (n=3 [18%]), and hypocalcaemia (n=3 [18%]). There were 12 serious adverse events in 11 (65%) patients. Three (18%) patients died due to treatment-related events (due to cardiomyopathy, pulmonary haemorrhage, and bone marrow aplasia). INTERPRETATION: Ponatinib-FLAG-IDA can induce second chronic phase in patients with blast-phase chronic myeloid leukaemia, representing an active salvage therapy to bridge to allogeneic HSCT. The number of treatment-related deaths is not in excess of what would be expected in this very high-risk group of patients receiving intensive chemotherapy. The efficient EffTox method is a model for investigating novel therapies in ultra-orphan cancers. FUNDING: Blood Cancer UK and Incyte.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Copland M, Slade D, McIlroy G, et al. Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. Lancet Haematol. 2021. PMID: 34906334. doi:10.1016/S2352-3026(21)00370-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。